Literature DB >> 27612846

Surgery for Diabetic Eye Complications.

María H Berrocal1, Luis A Acaba2, Alexandra Acaba3.   

Abstract

New modalities for the treatment of diabetic eye complications have emerged in the past decade. Nevertheless, many severe diabetic retinopathy complications can only be treated with vitreoretinal surgery. Technological advances in pars plana vitrectomy have expanded the gamut of pathologies that can be successfully treated with surgery. The most common pathologies managed surgically include vitreous opacities and traction retinal detachment. The indications, surgical objectives, adjunctive pharmacotherapy, microincisional surgical techniques, and outcomes of diabetic vitrectomy for proliferative diabetic retinopathy and diabetic tractional retinal detachment will be discussed. With the availability of new microincisional vitrectomy technology, wide angle microscope viewing systems, and pharmacologic agents, vitrectomy can improve visual acuity and achieve long-term anatomic stability in eyes with severe complications from proliferative diabetic retinopathy.

Entities:  

Keywords:  Diabetic retinopathy; Traction retinal detachment; Vitrectomy; Vitreous hemorrhage

Mesh:

Year:  2016        PMID: 27612846     DOI: 10.1007/s11892-016-0787-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  36 in total

1.  Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy.

Authors:  Pascale Massin; Graham Duguid; Ali Erginay; Belkacem Haouchine; Alain Gaudric
Journal:  Am J Ophthalmol       Date:  2003-02       Impact factor: 5.258

2.  Transconjunctival sutureless 23-gauge vitrectomy.

Authors:  Claus Eckardt
Journal:  Retina       Date:  2005 Feb-Mar       Impact factor: 4.256

3.  Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome.

Authors:  Chung-May Yang; Pei-Yuang Su; Po-Ting Yeh; Muh-Shy Chen
Journal:  Can J Ophthalmol       Date:  2008-04       Impact factor: 1.882

4.  The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage.

Authors:  Sule Berk Ergun; Yasin Toklu; Hasan Basri Cakmak; Sabri Raza; Saban Simsek
Journal:  Semin Ophthalmol       Date:  2014-01-10       Impact factor: 1.975

5.  INTRASURGICAL MICROSCOPE-INTEGRATED SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY-ASSISTED MEMBRANE PEELING.

Authors:  Christiane I Falkner-Radler; Carl Glittenberg; Max Gabriel; Susanne Binder
Journal:  Retina       Date:  2015-10       Impact factor: 4.256

6.  Vitreous contraction in proliferative diabetic retinopathy.

Authors:  M D Davis
Journal:  Arch Ophthalmol       Date:  1965-12

7.  Vitrectomy for diabetic traction retinal detachment involving the macula.

Authors:  T A Rice; R G Michels; E F Rice
Journal:  Am J Ophthalmol       Date:  1983-01       Impact factor: 5.258

8.  Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease.

Authors:  M Ali Khan; Abtin Shahlaee; Brian Toussaint; Jason Hsu; Arunan Sivalingam; Pravin U Dugel; Rohit R Lakhanpal; Christopher D Riemann; Maria H Berrocal; Carl D Regillo; Allen C Ho
Journal:  Am J Ophthalmol       Date:  2015-09-28       Impact factor: 5.258

9.  Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.

Authors:  Yusuke Oshima; Chiharu Shima; Taku Wakabayashi; Shunji Kusaka; Fumio Shiraga; Masahito Ohji; Yasuo Tano
Journal:  Ophthalmology       Date:  2009-03-09       Impact factor: 12.079

10.  Incidence of cataract extraction after diabetic vitrectomy.

Authors:  William E Smiddy; William Feuer
Journal:  Retina       Date:  2004-08       Impact factor: 4.256

View more
  8 in total

Review 1.  Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.

Authors:  Elia J Duh; Jennifer K Sun; Alan W Stitt
Journal:  JCI Insight       Date:  2017-07-20

Review 2.  Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society).

Authors:  Borja Corcóstegui; Santiago Durán; María Olga González-Albarrán; Cristina Hernández; José María Ruiz-Moreno; Javier Salvador; Patricia Udaondo; Rafael Simó
Journal:  J Ophthalmol       Date:  2017-06-14       Impact factor: 1.909

Review 3.  Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy.

Authors:  Ana R Santiago; Raquel Boia; Inês D Aires; António F Ambrósio; Rosa Fernandes
Journal:  Front Physiol       Date:  2018-07-13       Impact factor: 4.566

4.  Patients' Experience of Anxiety and Pain during Retrobulbar Injections prior to Vitrectomy.

Authors:  Michael Mimouni; Hamza Abualhasan; Kamal Mtanes; Fares Mazzawi; Yoreh Barak
Journal:  J Ophthalmol       Date:  2019-07-31       Impact factor: 1.909

5.  Risk Factors of Neovascular Glaucoma After 25-gauge Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage: A Retrospective Multicenter Study.

Authors:  Kei Takayama; Hideaki Someya; Hiroshi Yokoyama; Yoshihiro Takamura; Masakazu Morioka; Seiji Sameshima; Tetsuo Ueda; Shigehiko Kitano; Maki Tashiro; Masahiko Sugimoto; Mineo Kondo; Taiji Sakamoto; Masaru Takeuchi
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

6.  Pars Plana Vitrectomy Reoperations for Complications of Proliferative Diabetic Retinopathy.

Authors:  Hasenin Al-Khersan; Michael J Venincasa; Amy Kloosterboer; Jayanth Sridhar; William E Smiddy; Justin H Townsend; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2020-06-10

Review 7.  New Insights into Treating Early and Advanced Stage Diabetic Retinopathy.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

Review 8.  The Oxidative Stress and Mitochondrial Dysfunction during the Pathogenesis of Diabetic Retinopathy.

Authors:  Meng-Yu Wu; Giou-Teng Yiang; Tzu-Ting Lai; Chia-Jung Li
Journal:  Oxid Med Cell Longev       Date:  2018-09-05       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.